Living donor liver transplantation for congenital hepatic fibrosis in children

Pathol Int. 2020 Jun;70(6):348-354. doi: 10.1111/pin.12917. Epub 2020 Mar 2.

Abstract

Congenital hepatic fibrosis (CHF) often accompanies autosomal recessive polycystic kidney disease (ARPKD), which stems from a PKHD1 gene mutation. The aim of this study was to clarify the prognosis of children with CHF who received living donor liver transplantation (LDLT) from donors who might be heterozygous carriers of a hepatorenal fibrocystic disease. Fourteen children with CHF who underwent LDLT at our center were enrolled. Eight and two patients had ARPKD and nephronophthisis, respectively. Eight of the donors were the recipients' fathers, and six donors were their mothers. We examined the histological and radiological findings of the donor livers and complications in the recipients following the liver transplantation. Seven of the donor livers presented morphological abnormalities of the bile ducts. Abdominal computed tomography revealed liver cysts in eight donors. One recipient underwent re-LT for graft failure due to rejection. Three patients presented with rejection, and one presented with sepsis. The overall survival rate was 100% and the original graft survival rate was 93%. In conclusion, the prognosis of recipients who received a LDLT from their parents for CHF was excellent. However, the morphology of half the donor livers was abnormal. Careful follow-up is needed to ensure long-term graft survival.

Keywords: children; combined liver-kidney transplantation; congenital hepatic fibrosis; living donor liver transplantation.

MeSH terms

  • Adolescent
  • Adult
  • Allografts / pathology*
  • Child
  • Child, Preschool
  • Female
  • Genetic Diseases, Inborn / surgery*
  • Heterozygote
  • Humans
  • Liver Cirrhosis / surgery*
  • Liver Transplantation / methods*
  • Living Donors*
  • Male
  • Middle Aged
  • Treatment Outcome

Supplementary concepts

  • Hepatic Fibrosis, Congenital